Rani Therapeutics (RANI) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

50NeutralDD: Sep 18, 2026Analyst: 58

paidPrice at analysis date

USD 0.84 (18/09/2026)

domainMkt cap

$160M

pie_chartShares

candlestick_chart52W

trending_downShort interest

8.5%

MEDIUMNASDAQHealth Care70 employeesFounded 2012

Verdict: Moderately Attractive — Speculative

Real IP moat (RaniPill oral delivery of biologics) validated by positive Phase 1a RT-114 obesity data (>150% bioavailability vs SC injection). But: sub-$100M microcap, cash runway only through 2027, imminent Nasdaq delisting/reverse-split deadline (Nov 9, 2026), and a crowded oral GLP-1 race where Novo & Lilly are already commercial. Binary bet with real upside but structural dilution overhang.

📊 DIANALITICS RESEARCH INDEX Company & Thesis Assessment Score /100 — updated 2026-09-18

Rani Therapeutics (RANI)

Clinical-stage biotech / drug delivery · NASDAQ · San Jose, CA

"Real platform, tight cash, binary catalysts, delisting overhang."

Platform IP RT-114 pos. Delisting risk Cash tight Late GLP-1

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — rNPV probability-weighted + cash floor

Fair value base case

USD 1.40

Range: USD 0.35-USD 3.50

Price at analysis date: USD 0.84 (18/09/2026)

Base upside/downside: +67%

rNPV probability-weighted sum-of-parts. Peak WW sales assumptions based on GLP-1 obesity TAM ($100B+ by 2030) with conservative Rani share; PoS assumptions in line with industry benchmarks (Phase 1 → approval ~10-15% for endocrine/metabolic drugs). Cross-check via comparable microcap oral-delivery peers (0.6-1.5x EV/cash). Sensitivity is wide — reflects the binary nature of Phase 1b readout, delisting outcome, and dilution timing. ⚠️ Not investment advice.

Component	Assumption	USD/share
Cash floor (net of debt)	$53.4M cash − $4.3M debt = $49.1M / 115M sh. FD (post-2025 PIPE)	+0.43
Chugai deal — risk-adj. NPV	$18M tech transfer × 60% + $57M dev × 20% + $100M sales × 5% + 4 option targets × $10M × 15% = ~$33M / 115M sh (unchanged assumptions vs prior DD)	+0.29
RT-114 rNPV (obesity, 50/50 w/ ProGen)	$800M peak WW sales × 50% Rani share × 15% PoS × 6x rev NPV multiple / 115M sh = ~$90M rNPV, re-rated post-Phase-1a positive readout	+0.78
RT-102 + other legacy pipeline	Oral PTH (osteoporosis) + RT-111 immunology + RT-116: 15% probability × $50M aggregate platform value / 115M sh = ~$7.5M rNPV (right-sized vs prior "other" $0.09)	+0.13
PegBio + platform partnerships (new)	PegBio MOU (Jul-26) + 2 additional partner slots × 20% probability × $50M rNPV each = ~$25M option value / 115M sh	+0.22
Cash burn to next milestone	~$25M burn 12 months (Phase 1b start) reduces cash floor: −$25M / 115M	−0.22
Dilution haircut (equity raise 2027)	60% probability × 25% dilution at ~$1/sh to fund Phase 1b/2 = ~15% expected dilution on residual value	−0.23
FV base case	Sum: 0.43 + 0.29 + 0.78 + 0.13 + 0.22 − 0.22 − 0.23	≈ $1.40

Bull

$2.80–$3.50

Probability: 25%

Phase 1b positive readout 2027 confirms oral GLP-1 efficacy + weight loss ≥5% in obese patients. Pharma partnership (Novo/Lilly/Pfizer) values RaniPill delivery layer at $200-400M. Multiple platform deals from PegBio expansion. Reverse split executed, stock re-lists cleanly.

Base

$1.20–$1.60

Probability: 45%

Phase 1b delivers mixed data (bioavailability confirmed but weight loss <5%). RT-114 continues but partnered economics limit upside. Reverse split executes, additional $30-50M equity raise at $1-1.50 post-split. Platform validated but not breakout.

Bear

$0.30–$0.50

Probability: 30%

Phase 1b delayed or misses primary endpoint. Cash reaches critical level Q3 2027; forced raise at deep discount (30%+ dilution). Nasdaq delisting to OTC pink sheets if reverse split rejected or fails to hold $1. Platform becomes orphaned research asset.

Methodology: rNPV probability-weighted sum-of-parts. Peak WW sales assumptions based on GLP-1 obesity TAM ($100B+ by 2030) with conservative Rani share; PoS assumptions in line with industry benchmarks (Phase 1 → approval ~10-15% for endocrine/metabolic drugs). Cross-check via comparable microcap oral-delivery peers (0.6-1.5x EV/cash). Sensitivity is wide — reflects the binary nature of Phase 1b readout, delisting outcome, and dilution timing. ⚠️ Not investment advice. Not investment advice.

warning

🚨 Nasdaq Minimum Bid Deficiency — Compliance Deadline Nov 9, 2026

On May 11, 2026 Rani received a Nasdaq notice for failing the $1.00 minimum bid rule over 30 consecutive trading days. First 180-day compliance window ends 2026-11-09. Path to compliance: either the stock closes ≥$1.00 for 10 consecutive sessions before that date, or the company transfers to Nasdaq Capital Market for a second 180-day window (likely) and/or executes a reverse stock split. Reverse split creates an immediate sentiment overhang and typically triggers post-split selling pressure in microcap biotech.

warning

🔄 FV reconciliation vs prior report

Fair value raised from $0.80 (DD dated 2026-06-12) to $1.40 ( +75% ). Drivers, net: (a) +$0.25 RT-114 rNPV re-rated after positive Phase 1a readout Aug-13-2026 (>150% bioavailability vs SC injection) — probability of Phase 1b success moved from 30% pre-readout to ~50% platform-validated; (b) +$0.22 new PegBio 3-year metabolic MOU signed Jul-9-2026 (did not exist in prior report); (c) +$0.04 higher cash after Q1-2026 $20M registered direct; (d) +$0.04 lower expected dilution ($0.23 vs $0.21 prior, offset by burn timing). Chugai deal rNPV kept at $0.29/sh (essentially unchanged from prior $0.30). RT-102 + legacy pipeline slightly upsized to $0.13 (vs $0.09 prior) to reflect PegBio-adjacent momentum. Base thesis unchanged: speculative platform bet with hard cash anchor; dilution + Nasdaq compliance overhangs both remain.

check_circle

✅ Positive Phase 1a Data for RT-114 (Aug 2026)

RT-114 (oral GLP-1/GLP-2 dual agonist PG-102, partnered 50/50 with ProGen) achieved systemic exposure >150% relative to matched 12mg subcutaneous dose, with no serious adverse events attributed to the RaniPill capsule. This is the single most important data point of the platform's history: it validates the RaniPill can deliver peptide biologics at supra-injection bioavailability. Phase 1a expansion cohort dosed; Phase 1b obesity study starts end-2026, data 2027.

⚠️ Methodology note: Clinical-stage biotech pre-approval profile. Fair value method = rNPV (risk-adjusted NPV) probability-weighted across pipeline programs + cash floor. Traditional peer multiples (P/S, EV/EBITDA) not meaningful given contract-only revenue ($1.7M Q2). Cross-check via platform value (comparable oral-delivery peers Assertio, Entera Bio, Chinook when applicable) and sum-of-parts.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

~8.5%

9.1M shares short on ~107M float, +826% YoY. Days-to-cover ~4-5 on typical volume. Elevated for a microcap; reflects delisting fears and burn concerns. Short squeeze catalyst = Phase 1b positive data + partnership announcement.

🔴 Share dilution (1Y)

+35%

From ~85M to ~115M sh. Sep25 → Sep26. Drivers: Oct-2025 $60.3M private placement + Q1-2026 $20M registered direct + RSU vesting. Additional 20-30% dilution likely in 2027 to fund Phase 1b/2.

🔴 Buyback

No repurchase program. Capital priority is Phase 1b initiation + Nasdaq compliance. Reverse split is the only near-term "share reduction" action, and it is not a buyback.

Short Interest — context

RANI — ~8.5%

8.5%

Insider transactions last 12 months: no red-flag single sale >$500K identified in public filings. New CFO Nicholas Maestas appointed Q2 2026; Michelle Gilson joined the board. No class actions, no SEC investigation, no short-seller report on file — the delisting risk is purely mechanical (share price), not fundamental/legal.

$Financial analysis — FY26E

Q2 2026 revenue

$1.7M

Contract revenue only

Q2 2026 net loss

−$8.4M

Improved from −$11.2M YoY

Cash (Jun-26)

$53.4M

Runway "through 2027" (mgmt)

Net cash / share

$0.43

~51% of stock price

Item ($M)	FY22	FY23	FY24	FY25	FY26E
Contract revenue	2.1	3.4	2.8	5.5	~6–8
R&D expense	40.2	43.5	32.0	27.1	~28–32
G&A expense	21.4	18.0	14.5	11.8	~11–13
Net loss	−59.5	−58.2	−43.8	−33.4	~−32 to −36
Cash (EoP)	96.5	52.1	44.0	85.3	~40
Shares outstanding (M)	28	35	52	85	~115

Note: FY = calendar year. FY25 cash boosted by Oct-25 $60.3M PIPE. FY26E incorporates $20M Q1 registered direct + Q2 burn trajectory. Structural burn ~$8-10M/quarter with recent cost discipline.

Quarterly dynamics — last 5 quarters
Metric	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue ($M)	1.2	1.5	2.0	1.6	1.7
Gross margin %	n/m	n/m	n/m	n/m	n/m
Net loss ($M)	−11.2	−9.5	−8.8	−9.0	−8.4
End-of-period cash ($M)	32.4	78.9	85.3	68.0	53.4

Financial position and sustainability

Cash runway (at Q2 burn rate)

~5–6 quarters

Net cash / Market cap

52%

Shares dilution 3Y

+310% (28M → 115M)

Nasdaq bid compliance (days left)

~52 days to Nov 9

account_tree

Business model — RaniPill oral biologics platform

Rani Therapeutics: robotic capsule to replace injections

Rani develops the RaniPill®, a proprietary self-orienting robotic capsule that delivers biologics (peptides, antibodies, hormones) orally with injection-comparable bioavailability. The pill dissolves selectively in the intestine and deploys a tiny needle into the intestinal wall (no pain receptors) to inject the payload. Founded in 2012 out of InCube Labs; IPO'd Jul 2021. Business model shifted post-IPO from wholly-owned pipeline to a hybrid model: two internal candidates (RT-102, RT-105) + partner-funded pipeline (RT-114 with ProGen 50/50 economics; PegBio 3-year metabolic MOU; historical partnerships with Chugai, Celltrion). Model is capital-light for Rani once a partnership is signed — partners fund development and share revenue.

RT-114 (Obesity — ProGen 50/50) Peak $500-800M WW / Rani 50% 🟢 Phase 1b start end-2026 Oral GLP-1/GLP-2 dual agonist (PG-102). Phase 1a: >150% bioavailability vs SC. 50/50 cost + revenue share. Highest-conviction near-term catalyst; obesity market is the mega-TAM ($100B+ by 2030). Late in the race vs Lilly/Novo but different mechanism (peptide vs small molecule). RT-102 (Osteoporosis) Peak $200-300M WW / Rani 100% 🟡 Phase 2-ready Oral PTH via RaniPill GO. Completed Phase 1. Next step: partnership or Phase 2 initiation. Competing with Radius/Ascendis Pharma. Value depends on partnership terms; standalone development is capital-intensive. Platform partnerships $5-8M contract rev + milestones 🟢 PegBio MOU active PegBio 3-year MOU on metabolic candidates. Historical fee-for-service deals with big pharma (Chugai, Celltrion). Partners fund R&D; Rani receives upfront + milestones + royalties. Each new deal = ~$5-15M upfront + option value.

gavel

Legal, regulatory and risk analysis

Nasdaq delisting / reverse split

Critico

Stock <$1 since early 2026. First compliance window ends Nov 9, 2026. Second 180-day window likely available on Nasdaq Capital Market. Reverse split (1:5 or 1:10) is the near-certain path — creates immediate sentiment headwind and typical post-split selling.

Cash runway ends 2027

Alto

$53.4M cash + ~$32-35M annual burn = ~5-6 quarters runway. Phase 1b/2 costs will accelerate burn to $40-50M/year. Equity raise in 2027 near-certain, likely at price below current level = deeper dilution.

Late entry in oral GLP-1 race

Alto

Novo's oral semaglutide (Dec 2025) and Lilly's orforglipron (Apr 2026) already commercial. Pfizer, AstraZeneca, Regor in Phase 3. RT-114 differentiator = peptide vs small molecule + partnership economics, but market may already be locked up by 2028-29.

Phase 1b binary readout

Critico

RT-114 Phase 1b data 2027 is the make-or-break event. Success = platform validation + potential big-pharma deal. Failure or ambiguous weight-loss data = terminal thesis damage, cash fire-sale scenario.

Concentration in a single partner

Moderato

RT-114 economics fully dependent on ProGen relationship. If ProGen halts PG-102 development for its own reasons, Rani loses the primary value driver. Mitigant: 50/50 economics give Rani co-development rights.

Reverse split execution risk

Moderato

Historical microcap biotech pattern: reverse splits typically underperform 20-40% in the following 6 months due to forced selling from index funds and retail investors' anchoring bias. Consensus PT revisions likely lag.

Positive Phase 1a data validates platform

Positivo

RT-114 bioavailability >150% vs SC injection is a landmark data point — solves the fundamental "does the pill deliver biologics?" question. Real IP moat with patents on the capsule mechanism.

Obesity/GLP-1 mega-TAM

Positivo

Global obesity drug market $100B+ by 2030; oral GLP-1 subset projected >1/3 of total. Even a 0.5% share via RT-114 = $500M peak sales. Partnership economics limit but don't cap value.

article

SWOT analysis

Strengths

+Proprietary RaniPill IP with proven >150% bioavailability data.
+Partner-funded model reduces capital burden (ProGen 50/50, PegBio MOU).
+Net cash = 51% of current market cap = downside anchor.
+No litigation, no SEC probe, no short-seller report.

Weaknesses

−Cash runway only through 2027 → forced dilution.
−Stock below $1 → Nasdaq delisting/reverse split imminent.
−History of ~35% annual dilution via PIPEs and ATMs.
−Contract revenue only, no product on market until 2029+.

Opportunities

→RT-114 Phase 1b readout 2027 = binary re-rating catalyst.
→Big-pharma partnership on RaniPill delivery layer.
→PegBio MOU expansion to specific candidate deals.
→Platform application beyond obesity (rare disease, autoimmune).

Threats

!Oral GLP-1 market locked by Lilly/Novo before RT-114 launch.
!Phase 1b failure or ambiguous weight-loss endpoint.
!Reverse split triggers 20-40% post-split drawdown historically.
!ProGen unilateral halt of PG-102 kills RT-114 economics.

article

Summary by assessment area

Fair Value verdict

Base FV $1.40 = +67% vs $0.84 close.
Bull $3.15 (25%), Base $1.40 (45%), Bear $0.40 (30%).
Prob-weighted FV ≈ $1.53.
Wide range reflects binary Phase 1b outcome.

Investment thesis check

Real platform IP validated by Phase 1a data.
Partnered pipeline reduces cash-burn risk to Rani.
Cash floor + platform option value = downside cushion.
But: delisting overhang + dilution are near-term negatives.

Position sizing note

Speculative sizing only (≤1-2% of portfolio).
Best entry window: post-reverse-split drawdown (2026 Q4).
Set hard stop below cash-per-share floor (~$0.35 adjusted).
Not suitable for concentrated or income portfolios.

Sources & Disclaimer

Sources: Rani Therapeutics Q2 2026 press release & Form 10-Q (SEC), Aug-13-2026 corporate update, Nasdaq deficiency notice 8-K (2026-05-11), Phase 1a RT-114 data announcement (BioSpace/Rani IR), PegBio collaboration announcement (2026-07-09), ProGen 50/50 collaboration agreement (Jun 2024), Yahoo Finance historical prices, Investing.com quote (Sep 16-17 2026). Market data — last verified close 2026-09-17. This document is for informational purposes only and does not constitute financial or investment advice.